Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports
03/07/2025 15:34
July 3 (Reuters) - Summit Therapeutics SMMT.O is considering an up to $15 billion partnership with AstraZeneca AZN.L, Bloomberg News reported on Thursday, citing people familiar with the matter. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering